Hospira Voluntarily Recalls One Lot of Lidocaine HCl Injection

Lake Forest, Ill.-based Hospira has voluntarily recalled one lot of Lidocaine HCl Injection, USP, 2%, a local anesthetic, due to particles floating in the solution.

Advertisement

If administered, the particle could either block the passage of the solution to the patient and delay therapy or pass from the catheter into the patient, causing local inflammation.

The news release notes the particle is reddish-orange in color. If this color is due to a presence of iron in the particle, it poses a risk to the patient if undergoing an MRI because the particle could be pulled through tissue from the magnetic connection.

The recalled expired lot is Lot 32-135-DD with the expiration date of Aug. 1, 2015.

More Articles on the FDA:

FDA, European Medicines Agency to Collaborate on Generic Drug Approvals
FDA, CMS Extend Parallel Review Program
FDA Names GS1 First Accredited Issuing Agency for UDIs

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

From fragmentation to operational flow: Solving the healthcare workforce puzzle

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenters: Dr. Pat Hunt, QGendaAndrea Daugherty, MHA, CISSP, CHCIO, CDH-E, Arrowhead Regional Medical CenterElizabeth Lindsay-Wood, MBA, CHCIO, CDH-E, Moffitt Cancer CenterDeb Muro, El Camino HealthJohn Tejeda, D.H.A., MLS, MPAS, DFAAPA, LSSBB, FACHE, Vascular and Neuroscience Institute

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.